US Health Secretary Cancels Half a Billion Dollars in Vaccine Projects
Robert F. Kennedy Jr announced on August 6, 2025 that the Department of Health and Human Services will abandon 22 mRNA‑based vaccine initiatives, diverting funds toward a “universal vaccine” that aims to replicate natural immunity.
Key Points of the Pivot
- Funding cut: Over $500 million (€432 million) approved for vaccine development will be redirected.
- Project cancellation: 22 mRNA‑driven research efforts, including those run by Pfizer and Moderna, are slated for termination.
- Strategic goal: A single jab that could defend against COVID‑19, influenza, and potential future pandemics.
Expert Reaction
The decision has sparked backlash from public health professionals across the United States, who criticize the move as “dangerous, short‑sighted, and unsupported by current science.”
Next Steps
For the next 12–18 months, the Department will allocate resources toward research on broader, safer vaccine strategies, with the objective of creating a comprehensive, all‑in‑one immunization protocol.
Most Read on Euro Weekly News
CDC votes to phase out controversial mercury-based ingredient in flu vaccines
RFK Jr’s rise fuels vaccine doubts across Europe
Kennedy touts universal, all-in-one jab that ‘mimics natural immunity’
Alaska Health Director Jumps to Cancel mRNA Vaccines
Anchorage, Alaska — A rapid policy shift announced hours after a federal hearing saw the Health Department cancel 22 mRNA vaccine contracts. Director Kevin Kennedy called the move a decisive step toward “safer, broader vaccine platforms” that remain effective even as viruses mutate.
Key Points of the Decision
- Failed Protection – 22 mRNA investments ended because data showed vaccines did not protect against upper‑respiratory illnesses like COVID and flu.
- Shift in Priorities – The cancellation was framed as a “shift in vaccine development priorities.”
- Targeted Platforms – Funding will redirect toward platforms with broader, mutation‑resistant effectiveness.
Officials’ Rationale
In a video posted to X, Kennedy said:
“We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively.”
Medical Community Reacts
Replies came quickly and were highly critical.
Mike Osterholm (University of Minnesota, infectious disease expert)
“I don’t think I’ve seen a more dangerous decision in public health in my 50 years in the business,” he said, cited by Sky News.
Dr. Paul Offit (Children’s Hospital of Philadelphia)
“It’s certainly saved millions of lives,” he said, pointing to mRNA vaccines that helped halt the COVID‑19 pandemic.
What This Means for the Public
- Funding Redistribution – $22 mRNA projects removed, with money flowing to mutation‑resistant vaccine research.
- Effectiveness Question – Critics question whether the new platforms will truly outpace evolving viruses.
- Public Health Impact – Some experts fear the decision undermines a tool that halted a global pandemic.
Final Thought
Health officials today appear to be altering the future of vaccine technology. The long‑term outcome of abolishing 22 mRNA contracts remains a matter of intense debate, with the stakes set high for future respiratory disease threats worldwide.
What is mRNA?
Reimagining mRNA vaccines: A new route to protection
How mRNA vaccines work
Rather than using live virus, these shots deliver a genetic template that instructs the body to produce a harmless viral protein, triggering an immune response.
Accelerating vaccine production
The UK Health Security Agency points out that this method speeds up manufacturing. Moderna had previously highlighted how mRNA could quicken flu vaccine development.
Department response to criticism
Other mRNA uses remain intact
- Research into cancer therapies continues uninterrupted.
- Studies of various diseases proceed unaffected.
Kennedy’s controversial actions
- Fired the advisory panel that recommends vaccines.
- Scaled back COVID‑19 vaccine guidance.
- Refrained from endorsing any jab, despite a worsening U.S. measles outbreak.
Experts warn of rising vaccine hesitancy and lowered pandemic preparedness
The larger question remains: will a universal jab truly deliver?
